European Medicines Agency confirms further restrictions on drug Zinbryta
Contributed by NAMPA / Xinhua.
BRUSSELS, Nov. 10 (Xinhua) -- The European Medicines Agency (EMA) on Friday confirmed further restrictions on the medicine Zinbryta to reduce the risk of serious liver damage.
EMA said in a press release that this medicine will be used in a restricted patient group, with strict liver monitoring.
Zinbryta is a medicine used to treat certain patients with relapsing forms of multiple sclerosis. It contains the active substance daclizumab and was authorized in the European Union in July 2016.